Correlation Between Alnylam Pharmaceuticals and Replimune

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Alnylam Pharmaceuticals and Replimune at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Alnylam Pharmaceuticals and Replimune into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Alnylam Pharmaceuticals and Replimune Group, you can compare the effects of market volatilities on Alnylam Pharmaceuticals and Replimune and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Alnylam Pharmaceuticals with a short position of Replimune. Check out your portfolio center. Please also check ongoing floating volatility patterns of Alnylam Pharmaceuticals and Replimune.

Diversification Opportunities for Alnylam Pharmaceuticals and Replimune

0.34
  Correlation Coefficient

Weak diversification

The 3 months correlation between Alnylam and Replimune is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Alnylam Pharmaceuticals and Replimune Group in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Replimune Group and Alnylam Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Alnylam Pharmaceuticals are associated (or correlated) with Replimune. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Replimune Group has no effect on the direction of Alnylam Pharmaceuticals i.e., Alnylam Pharmaceuticals and Replimune go up and down completely randomly.

Pair Corralation between Alnylam Pharmaceuticals and Replimune

Given the investment horizon of 90 days Alnylam Pharmaceuticals is expected to under-perform the Replimune. In addition to that, Alnylam Pharmaceuticals is 1.16 times more volatile than Replimune Group. It trades about -0.25 of its total potential returns per unit of risk. Replimune Group is currently generating about -0.13 per unit of volatility. If you would invest  1,201  in Replimune Group on August 24, 2024 and sell it today you would lose (96.00) from holding Replimune Group or give up 7.99% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Alnylam Pharmaceuticals  vs.  Replimune Group

 Performance 
       Timeline  
Alnylam Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Alnylam Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.
Replimune Group 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Replimune Group are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite quite conflicting basic indicators, Replimune may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Alnylam Pharmaceuticals and Replimune Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Alnylam Pharmaceuticals and Replimune

The main advantage of trading using opposite Alnylam Pharmaceuticals and Replimune positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Alnylam Pharmaceuticals position performs unexpectedly, Replimune can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Replimune will offset losses from the drop in Replimune's long position.
The idea behind Alnylam Pharmaceuticals and Replimune Group pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data